Recent

% | $
Quotes you view appear here for quick access.

Zynga, Inc. Message Board

dtanger 155 posts  |  Last Activity: Aug 28, 2015 12:46 PM Member since: May 5, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • dtanger@bellsouth.net by dtanger Aug 28, 2015 12:46 PM Flag

    treating prostatitis ...now this would shut everyone up as to the long asked question...IS THIS PRODUCT A SUPERIOR ANTI INFLAMMATORY or NOT ?
    I sold all of my shares after holding for close to 6 years b/c i believe in the benefits of taking Anatabloc that being said. After losing too much $$ and just wanting to be clean of what I saw as dealing with a DRAMA Company moved on.
    Lessons learned --sure short or long one can always have grace and class when jotting ideas on a message board.
    MAy the direction of the company henceforth be as stellar as the product they are attempting to deliver back to market.
    Good success to those who remain.

  • OPK is rated BUY, based on the average of 4 Wall Street analyst ratings. Among these analysts, 75.0% (3) of them have positive ratings on the stock. 0.0% (0) of them have negative ratings. 25.0% (1) of them have neutral ratings. Analysts have an average $20.67 Target Price on OPK, implying 82.9% Upside to its current price of $11.30.

    Sentiment: Strong Buy

  • Financial Update

    Our business is going through a significant transformation and as a result, our financial results are evolving into an operating company with substantial revenues. Bio-Reference had fiscal 2014 revenue of $832 million and operating profit of $83.4 million. In looking to their financial performance for 2015, Bio-Reference had revenue of $432 million the first six months of fiscal 2015, an almost 13% increase from the comparable period of 2014. Bio-Reference’s operating profit of $30.9 million for the first six months of 2015 represents a 25% increase over their 2014 operating profit. Given Bio-Reference’s historical seasonal trends, we expect the second half of 2015 to show continuing growth in earnings and profits. We further expect that the contributions of Bio-Reference, FineTech and EirGen, will create positive EBITDA (earnings before interest, income taxes, depreciation and amortization) for OPKO. Finally, we expect to continue to invest in research and development activities which, if successful, will result in ongoing improvement of our financial performance.

    We appreciate your support and confidence and we look forward to sharing further news of our progress.

    Sincerely,

    Phillip Frost, M.D.

    Chairman and Chief Executive Officer

    Sentiment: Strong Buy

  • ice Chairman, CTO 20,000 Purchase at $10.82 $216,325 24,591,033 dire

  • OPKO expects written notification of NDA acceptance along with the Prescription Drug User Fee Act (PDUFA) date in the FDA’s 74-Day letter, which the Company expects to receive by mid-August 2015.

  • After Hours Trading
    Follow
    Opko Health Inc (OPK) After Hours Trading
    OPK $10.70* unch
    *Delayed - data as of 08/25/2015 19:52 - Find a broker to begin trading OPK now Exchange: NYSE
    Industry: Health Care
    Community Rating: Bullish
    OPK
    RAD

    Edit Symbol List
    Symbol Lookup
    SYMBOL LIST VIEWS
    FlashQuotes
    InfoQuotes
    STOCK DETAILS
    Summary Quote
    Real-Time Quote
    After Hours Quote
    Pre-market Quote
    Historical Quote
    Option Chain
    CHARTS
    Basic Chart
    Interactive Chart
    COMPANY NEWS
    Company Headlines
    Press Releases
    Market Stream
    STOCK ANALYSIS
    Analyst Research
    Guru Analysis
    Stock Report
    Competitors
    Stock Consultant
    Stock Comparison
    FUNDAMENTALS
    Call Transcripts
    Annual Report
    Income Statement
    Revenue/EPS
    SEC Filings
    Short Interest
    Dividend History
    HOLDINGS
    Ownership Summary
    Institutional Holdings
    Insiders
    (SEC Form 4)
    Save Stocks

    Aug. 25, 2015 Market Close: $ 10.70 Pre-Market Charts | After Hours Charts
    View most recent trades for the selected time period:
    After Hours Volume: After Hours High: After Hours Low:
    249,335 $ 10.842
    (16:06:29 PM) $ 10.61
    (17:45:51 PM)

    Trade Detail

    Most Active in the After-Hours

    Read more: http://www.nasdaq.com/symbol/opk/after-hours#ixzz3jsUt67D5

  • (NPG) Publisher of High Impact Scientific and Medical Information: ‘Rolapitant – a new and safer antiemetic agent’
    by Uncletlzz
    npg

    Rolapitant—a new and safer antiemetic agent

    NATURE REVIEWS CLINICAL ONCOLOGY | RESEARCH HIGHLIGHT

    CHEMOTHERAPY
    Rolapitant—a new and safer antiemetic agent

    Diana Romero
    Nature Reviews Clinical Oncology (2015) doi:10.1038/nrclinonc.2015.144
    Published online 25 August 2015

    (Excerpt)

    Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared adverse effects of chemotherapy. Now, three trials, all coordinated by Lee Schwartzberg and Bernardo Rapoport, show that rolapitant is a novel, safe and effective agent for the prevention of CINV.

    Diana Romero
    Imperial College London, London
    Cancer Research, Cell Biology, Molecular Biology
    PhD

  • - Yahoo - Tradingview - Stocktwits - SEC
    SEC Form 4
    Trade Date
    Ticker
    Insider
    Title
    Shares
    Insider Trade
    Value
    Owned
    Held
    Aug 25 07:04:45
    MAug 24 2015
    OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 223,600 Purchase at $10.99 $2,458,078 157,002,043 indirect
    Aug 24 07:53:41
    Aug 20 2015
    OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 34,375 Grant at $0.00 $0 156,593,443 indirect
    Aug 24 07:53:41
    Aug 21 2015
    OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 185,000 Purchase at $12.24 $2,264,345 156,778,443 indirect
    Aug 20 17:09:38
    Aug 20 2015
    OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 544,000 Purchase at $12.32 $6,702,134 156,559,068 indirect
    Aug 20 17:09:12
    MAug 20 2015
    OPK Rubin Steven D EVP-Administration 2,000 Purchase at $12.40 $24,799 5,441,407 direct
    DAug 19 10:28:23
    Aug 18 2015
    OPK Yu Alice Lin-Tsing Director 20,000 Option exercise at $2.05 $41,000 60,000 direct
    DAug 13 14:55:56
    Aug 12 2015
    OPK Baron Robert A Director 5,000 Option exercise at $0.41 $2,050 295,965 direct
    DAug 13 14:55:56
    Aug 12 2015
    OPK Baron Robert A Director 153 OptEx/tax payment at $13.45 $2,058 295,812 direct
    DAug 10 08:49:07
    MAug 7 2015
    OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 1,056,574 Option exercise at $5.56 $5,878,686 3,068,951 direct
    DAug 10 08:48:27
    MAug 7 2015
    OPK Hsiao Jane Ph D Vice Chairman, CTO 200,000 Option exercise at $7.94 $1,588,500 24,571,033 direct
    DAug 7 08:50:17
    Aug 6 2015
    OPK Hsiao Jane Ph D Vice Chairman, CTO 144,823 Converted deriv at $7.07 $1,023,899 4,617,404 indirect
    DAug 7 08:49:11
    Aug 6 2015
    OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 1,049,971 Converted deriv at $7.07 $7,423,295 156,015,068 indirec

    Sentiment: Strong Buy

  • Al Et Md Phillip Frost
    ProfileInsider PurchasesInsider SalesNews
    Insider Trading: Purchases
    1 - 20Next
    Company Symbol Price Amount Relationship Remaning Holdings Date Form 4
    Idi, Inc.
    IDI $7.91 5,000 Large Shareholder 4,859,588 2015-08-13 Filing
    Ladenburg Thalmann Financial Services Inc
    LTS $2.64 7,500 Director, Large Shareholder 12,636,199 2015-08-13 Filing
    Ladenburg Thalmann Financial Services Inc
    LTS $2.70 10,000 Director, Large Shareholder 12,628,699 2015-08-12 Filing
    Idi, Inc.
    IDI $7.58 5,000 Large Shareholder 4,854,588 2015-08-12 Filing
    Idi, Inc.
    IDI $7.66 5,000 Large Shareholder 4,849,588 2015-08-11 Filing
    Ladenburg Thalmann Financial Services Inc
    LTS $2.69 25,000 Director, Large Shareholder 12,618,699 2015-08-10 Filing
    Ladenburg Thalmann Financial Services Inc
    LTS $2.67 25,000 Director, Large Shareholder 12,593,699 2015-08-07 Filing
    Idi, Inc.
    IDI $10.41 10,000 Large Shareholder 4,844,588 2015-07-29 Filing
    Idi, Inc.
    IDI $8.96 5,000 Large Shareholder 4,834,588 2015-07-27 Filing
    Idi, Inc.
    IDI $7.04 25,000 Large Shareholder 4,829,588 2015-07-22 Filing
    Tiger X Medical, Inc.
    CDOM $0.10 10,000 Large Shareholder 34,178,877 2015-07-17 Filing
    Tiger X Medical, Inc.
    CDOM $0.09 1,100 Large Shareholder 34,168,877 2015-07-17 Filing
    Tiger X Medical, Inc.
    CDOM $0.10 45,000 Large Shareholder 34,167,777 2015-07-16 Filing
    Opko Health, Inc.
    OPK $16.67 1,800 Director, Officer, Large Shareholder 154,965,097 2015-07-08 Filing
    Opko Health, Inc.
    OPK $16.58 100 Director, Officer, Large Shareholder 154,963,297 2015-07-08 Filing
    Opko Health, Inc.
    OPK $16.57 1,100 Director, Officer, Large Shareholder 154,963,197 2015-07-08 Filing
    Opko Health, Inc.
    OPK $16.56 600 Director, Officer, Large Shareholder 154,962,097 2015-07-08 Filing
    Opko Health, Inc.
    OPK $16.52 1,800 Director, Officer, Large Shareholder 154,961,497 2015-07-08 Filing
    Opko Health, Inc.
    OPK $16.47 600 Director, Officer, Large Shareholder 154,959,697 2015-07-08 Filing
    Opko Health, Inc.
    OPK $16.46 1,200 Director, Officer, Large

    Sentiment: Strong Buy

  • dtanger@bellsouth.net by dtanger Aug 14, 2015 3:50 PM Flag

    now this is encouraging as to the swift up tick tempo of the investment community.

    Sentiment: Buy

  • OPKO’s Rolapitant has a great advantage over EMEND
    by Uncletlzz
    FinBuzz

    OPKO Health, Inc. (NYSE:OPK) PDUFA Goal Date on September 5th'

    FinancialBuzz
    13 Aug, 2015

    OPKO Health, Inc. (NYSE: OPK) is a biopharmaceutical and diagnostics company with a focus on developing a range of solutions to diagnose and treat serious medical conditions. The company is expecting a major catalyst for one of their product candidates, Rolapitant, for the treatment of chemotherapy-induced nausea and vomiting (CINV). The New Drug Application (NDA) for oral Rolapitant is under review by the U.S. Food and Drug Administration (FDA), with a PDUFA goal date scheduled for September 5, 2015.

    CINV is a condition from which about 6.6 million patients suffer from each year. The market opportunity in the United States alone is currently valued at approximately $1.25 billion. At the moment, Merck’s (NYSE: MRK) drug EMEND® is currently the most popular treatment for CINV, and judging by data from the phase 3 clinical trials, OPKO’s Rolapitant has a great advantage over EMEND. Rolapitant is a single dose long acting treatment, resulting in symptoms treated for as long as five days, comparing with one or two days from other drugs.

    OPKO has debt of $125 million (partially raised in the last quarter of 2014) and $220 million in cash. OPKO has a crucial license agreement for Rolapitant with Tesaro (NASDAQ: TSRO). According to the agreement OPKO is eligible to receive an up-front milestone payment of $121 million. The company is also entitled to double-digit royalties based on sales of the licensed medication, and a share of possible future profits from Rolapitant commercialization in Japan, as well as an option to market the product in Latin America.

    The stock is currently at a good entry point after a sharp selloff on June 3rd, when OPKO has announced a $1.47 billion acquisition of Bio-Reference (NASDAQ: BRLI), and another selloff followed on August 5th after the second quarter earnings report show

  • 7,200 Purchase at $16.56 $119,197 154,965,097 indirect
    Jul 8 07:01:11
    MJul 7 2015
    OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 5,400 Purchase at $16.64 $89,838 154,957,897 indirect
    Jul 7 06:46:03
    MJul 6 2015
    OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 3,600 Purchase at $16.07 $57,860 154,952,497 indirect
    Jul 6 06:40:53
    MJul 2 2015
    OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 9,000 Purchase at $16.13 $145,167 154,948,897 indirect
    Jul 1 17:38:43
    Jun 30 2015
    OPK Paganelli John A Director 100 Gift at $0.00 $0 299,725 direct
    Jun 30 06:43:05
    Jun 29 2015
    OPK Baron Robert A Director 2,000 Purchase at $15.81 $31,630 290,965 direct
    Jun 30 06:41:51
    MJun 29 2015
    OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 7,200 Purchase at $15.62 $112,471 154,939,897 indirect
    Jun 29 06:58:09
    MJun 26 2015
    OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 5,400 Purchase at $16.07 $86,779 154,932,697 indirect
    Jun 26 09:14:39
    MJun 25 2015
    OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 7,200 Purchase at $15.39 $110,774 154,927,297 indirect
    Jun 25 09:00:47
    MJun 24 2015
    OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 57,200 Purchase at $15.33 $876,775 154,920,097 indirect
    Jun 24 06:49:27
    MJun 23 2015
    OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 9,000 Purchase at $15.60 $140,428 154,862,897 indirect
    Jun 23 08:55:49
    MJun 22 2015
    OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 23,400 Purchase at $15.53 $363,351 154,853,897 indirect
    Jun 22 06:15:05
    MJun 19 2015
    OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 7,200 Purchase at $15.33 $110,363 154,830,497 indirect
    Jun 18 07:13:48
    MJun 17 2015
    OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 15,400 Purchase at $15.35 $236,416 154,823,297 indirect
    Jun 17 06:54:37
    MJun 16 2015
    OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 10,000 Purchase at $15.36 $153,628 154,807,897 indirect
    Jun 15 06:43:40
    MJun 12 2015
    OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 10,000 Purchase at $15.51 $155,099 154,7

    Sentiment: Strong Buy

  • CEO of Opko Health Inc. (OPK) Is Buying Millions of Shares… Again AUG 12, 2015 Sarah Roden Last Friday, Opko Health Inc. (NYSE:OPK) CEO P
    CEO of Opko Health Inc. (OPK) Is Buying Millions of Shares… Again
    AUG 12, 2015 Sarah Roden

    Sentiment: Strong Buy

  • CEO of Opko Health Inc. (OPK) Is Buying Millions of Shares… Again

    AUG 12, 2015 Sarah Roden
    Last Friday, Opko Health Inc. (NYSE:OPK) CEO Phillip Frost purchased more than one million shares of his company in five separate transactions valued at over $5.8 million. The multiple transactions were filed in one Form 4 with the SEC on August 10.

    As a CEO of the healthcare company, Frost was buying shares that he had purchased for exercise prices ranging from $2.36 to $8.37. At the time of his transactions on August 7, shares of OPK were trading at approximately $13.50. This type of deliberate and discretionary buy from a Corporate Insider often points to confidence in the company. Furthermore, Frost has a strong history buying and selling shares of his own companies in the past.

    According to TipRanks, Phillip Frost is the top-ranked Corporate Insider. When measured over one-year and no benchmark, Frost has an 81% success rate buying and selling shares of his own companies and a +51.5% average return per transaction. If you had followed Frost’s transactions on Opko since 2009, 82% of your transactions would have been profitable with an average return of 51% if you held each position for one year.

    Sentiment: Strong Buy

  • Reply to

    now long 77k vaxil "yeah baby "

    by sayz.simmon Jul 10, 2015 10:06 AM
    dtanger@bellsouth.net dtanger Aug 11, 2015 1:33 PM Flag

    Bid in right now for 6000 more ---not filled as yet.

    Sentiment: Buy

  • dtanger@bellsouth.net by dtanger Aug 10, 2015 2:22 PM Flag

    MabVax Therapeutics Holdings Provides Corporate Update and Reports Second Quarter 2015 Financial Results

    Google+ Share with LinkedIn


    SAN DIEGO, Aug. 10, 2015 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug development company, today provided a corporate update and reported financial results for the quarter ended June 30, 2015.

    "We are reporting progress toward achieving our near-term drug development milestones and with our capital formation," stated MabVax's President and Chief Executive Officer David Hansen. "We completed a $11.7 million equity financing led by OPKO Health, Inc., and its Chairman and Chief Executive Officer, biotech investor and entrepreneur Dr. Phillip Frost, which put MabVax in one of the best financial positions in our corporate history. We finished the second quarter with approximately $7.2 million in cash and equivalents, including the release on June 30, 2015, of $3.5 million of funds from the equity financing to the Company that were being held in escrow by OPKO Health, Inc. and Frost Gamma Investment Trust. We believe that our current cash position is sufficient to support our near-term drug discovery and development efforts."

    "The encouraging results from our non-human primate safety study for HuMab 5B1 further support our plan to file two Investigational New Drug applications, or INDs, with the FDA by 2015 year-end and begin both clinical trials in the first quarter of 2016," he added. "The GMP manufacturing of our clinical supplies of HuMab 5B1-based product for both clinical trials is on track for delivery in the fourth quarter of this year."

    MabVax plans to initiate two complementary Phase I clinical trials in the first quarter of 2016. One clinical trial is aimed at determining the safety and potential utility of HuMab 5B1 as a therapeutic agent in subjects with metastatic pancreatic cancer. The second clinical trial is aimed at demonstrating the utility of 89Z

  • dtanger@bellsouth.net by dtanger Aug 10, 2015 11:18 AM Flag

    Someone with conviction went shopping this morning...hummm

    Sentiment: Buy

  • SEC Form 4
    Trade Date
    Ticker
    Insider
    Title
    Shares
    Insider Trade
    Value
    Owned
    Held
    DAug 10 08:49:07
    MAug 7 2015
    OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 1,056,574 Option exercise at $5.56 $5,878,686 3,068,951 direct
    DAug 10 08:48:27
    MAug 7 2015
    OPK Hsiao Jane Ph D Vice Chairman, CTO 200,000 Option exercise at $7.94 $1,588,500 24,571,033 dire

  • Reply to

    Fox is watching the Hen house.

    by rf1sweet Aug 8, 2015 5:03 PM
    dtanger@bellsouth.net dtanger Aug 8, 2015 5:06 PM Flag

    YOU ARE HIRED !!!! If this was my invention you betcha I'd be pro active.

    Sentiment: Strong Buy

ZNGA
2.52+0.10(+4.13%)Aug 28 4:00 PMEDT